BridgeBio Q1 Revenues $194.5M, Initiates $500M Buyback and BBP-418 NDA
BridgeBio reported Q1 total revenues of $194.5M, driven by $180.6M U.S. net product revenue from Attruby and $9.5M royalty income. The company held $940.2M cash as of March 31, initiated a $500M share repurchase program and submitted its first NDA for BBP-418 with two more filings planned in 2026.
1. First Quarter Financial Results
BridgeBio reported total revenues of $194.5 million for Q1 2026, including $180.6 million of U.S. net product revenue from Attruby, $9.5 million in royalty income and $4.4 million in license and services revenue. The results reflect robust prescribing growth and patient persistence driving quarter-over-quarter momentum.
2. Attruby Commercial Momentum
Attruby’s global launch gained traction with recent approval in Brazil and continued uptake across treatment-naïve and experienced patient types. Real-world evidence shows a 43% reduction in diuretic intensification and significant outcome improvements versus tafamidis, reinforcing its differentiated profile.
3. Pipeline and NDA Filings
BridgeBio submitted its first NDA for BBP-418 in LGMD2I/R9 and expects to file NDAs for encaleret in ADH1 by mid-2026 and oral infigratinib in achondroplasia by Q3 2026, all programs potentially eligible for priority review. Preparations are underway for commercial launches in late 2026 or early 2027.
4. Share Repurchase Program
As of March 31, BridgeBio held $940.2 million in cash, cash equivalents and marketable securities. The Board authorized a $500 million share repurchase program to deploy capital toward stock repurchases, reflecting confidence in intrinsic value and financial strength.